{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:38:40Z","timestamp":1787002720221,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41391-025-01043-x","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:07:49Z","timestamp":1760746069000},"page":"411-417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["4K density: Adjusting the 4Kscore for prostate volume to improve risk stratification of clinically significant prostate cancer in men undergoing prostate biopsy"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5628-7951","authenticated-orcid":false,"given":"Timothy","family":"Guerard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao G.","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Nativ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cortizas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4497-3923","authenticated-orcid":false,"given":"Pedro","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archan","family":"Khandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Nahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-3372","authenticated-orcid":false,"given":"Chad","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gonzalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen J.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanoj","family":"Punnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"1043_CR1","unstructured":"Centers for Disease Control and Prevention. Prostate cancer incidence by stage at diagnosis. United States Cancer Statistics [Internet]. 2024 [cited 2025 Apr 21]. Available from: https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/prostate-cancer.html"},{"key":"1043_CR2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1056\/NEJM198710083171501","volume":"317","author":"TA Stamey","year":"1987","unstructured":"Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909\u201316. https:\/\/doi.org\/10.1056\/NEJM198710083171501.","journal-title":"N Engl J Med"},{"key":"#cr-split#-1043_CR3.1","unstructured":"National Cancer Institute. Prostate-specific antigen (PSA) test [Internet]. 2022 [updated 2022 Mar 1"},{"key":"#cr-split#-1043_CR3.2","unstructured":"cited 2025 Apr 21]. Available from: https:\/\/www.cancer.gov\/types\/prostate\/psa-fact-sheet"},{"key":"1043_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1006380306781","volume":"59","author":"MH Black","year":"2000","unstructured":"Black MH, Diamandis EP. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat. 2000;59:1\u201314. https:\/\/doi.org\/10.1023\/A:1006380306781.","journal-title":"Breast Cancer Res Treat"},{"key":"1043_CR5","doi-asserted-by":"publisher","first-page":"e077738","DOI":"10.1136\/bmj-2021-077738","volume":"377","author":"S Vaccarella","year":"2024","unstructured":"Vaccarella S, Li M, Bray F, Kvale R, Serraino D, Lorenzoni V, et al. Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. BMJ. 2024;377:e077738. https:\/\/doi.org\/10.1136\/bmj-2021-077738.","journal-title":"BMJ"},{"key":"1043_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","volume":"68","author":"DJ Parekh","year":"2015","unstructured":"Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015;68:464\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2014.10.021.","journal-title":"Eur Urol"},{"key":"1043_CR7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.juro.2017.11.113","volume":"199","author":"S Punnen","year":"2018","unstructured":"Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, et al. A multi-institutional prospective trial confirms noninvasive blood test maintains predictive value in African American men. J Urol. 2018;199:1459\u201363. https:\/\/doi.org\/10.1016\/j.juro.2017.11.113.","journal-title":"J Urol"},{"key":"1043_CR8","unstructured":"4Kscore. Detect your risk of aggressive prostate cancer | 4Kscore\u00ae test [Internet]. 2022 [cited 2025 Mar 12]. Available from: https:\/\/4kscore.com"},{"key":"1043_CR9","first-page":"3","volume":"17","author":"S Punnen","year":"2015","unstructured":"Punnen S, Pavan N, Parekh DJ. Finding the wolf in sheep\u2019s clothing: the 4Kscore is a novel blood test that can accurately identify the risk of aggressive prostate cancer. Rev Urol. 2015;17:3\u201313.","journal-title":"Rev Urol"},{"key":"1043_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.urology.2006.02.026","volume":"68","author":"PF Pinsky","year":"2006","unstructured":"Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL, et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology. 2006;68:352\u20136. https:\/\/doi.org\/10.1016\/j.urology.2006.02.026.","journal-title":"Urology"},{"key":"1043_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5489\/cuaj.3236","volume":"10","author":"NR Paterson","year":"2016","unstructured":"Paterson NR, Lavall\u00e9e LT, Nguyen LN, Witiuk K, Ross J, Mallick R, et al. Prostate volume estimations using magnetic resonance imaging and transrectal ultrasound compared to radical prostatectomy specimens. Can Urol Assoc J. 2016;10:264\u20138. https:\/\/doi.org\/10.5489\/cuaj.3236.","journal-title":"Can Urol Assoc J"},{"key":"1043_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.urology.2022.11.008","volume":"171","author":"S Choe","year":"2023","unstructured":"Choe S, Patel HD, Lanzotti N, Okabe Y, Rac G, Shea SM, et al. MRI vs. transrectal ultrasound to estimate prostate volume and PSAD: impact on prostate cancer detection. Urology. 2023;171:172\u20138. https:\/\/doi.org\/10.1016\/j.urology.2022.11.008.","journal-title":"Urology"},{"key":"1043_CR13","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1007\/s00345-020-03585-2","volume":"39","author":"C Stephan","year":"2021","unstructured":"Stephan C, Jung K, Lein M, Rochow H, Friedersdorff F, Maxeiner A. PHI density prospectively improves prostate cancer detection. World J Urol. 2021;39:3273\u20139. https:\/\/doi.org\/10.1007\/s00345-020-03585-2.","journal-title":"World J Urol"},{"key":"1043_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/bju.13762","volume":"120","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, et al. Prostate Health Index density improves detection of clinically significant prostate cancer. BJU Int. 2017;120:793\u20138. https:\/\/doi.org\/10.1111\/bju.13762.","journal-title":"BJU Int"},{"key":"1043_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0022-5347(17)37394-9","volume":"147","author":"MC Benson","year":"1992","unstructured":"Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol. 1992;147:817\u201321. https:\/\/doi.org\/10.1016\/S0022-5347(17)37394-9.","journal-title":"J Urol"},{"key":"1043_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/pros.24861","volume":"85","author":"CJ Britton","year":"2025","unstructured":"Britton CJ, Andrews JR, Arafa A, Kim Y, Latuche LR, Schulte PJ, et al. Prostate extracellular vesicles and prognostic biomarkers of clinically significant prostate cancer: a prospective single-institution pilot study. Prostate. 2025;85:594\u2013602. https:\/\/doi.org\/10.1002\/pros.24861.","journal-title":"Prostate"},{"key":"1043_CR17","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","volume":"186","author":"S Loeb","year":"2011","unstructured":"Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186:1830\u20134. https:\/\/doi.org\/10.1016\/j.juro.2011.06.057.","journal-title":"J Urol"},{"key":"1043_CR18","unstructured":"Food and Drug Administration. Summary of safety and effectiveness data (SSED) [Internet]. [cited 2025 May 2]. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf19\/P190022B.pdf"},{"key":"1043_CR19","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/pros.24078","volume":"80","author":"N Omri","year":"2020","unstructured":"Omri N, Kamil M, Alexander K, Edmond S, Ariel Z, David K, et al. Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume. Prostate. 2020;80:1444\u20139. https:\/\/doi.org\/10.1002\/pros.24078.","journal-title":"Prostate"},{"key":"1043_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.euf.2018.10.008","volume":"6","author":"NA Pickersgill","year":"2020","unstructured":"Pickersgill NA, Vetter JM, Andriole GL, Shetty AS, Fowler KJ, Mintz AJ, et al. Accuracy and variability of prostate multiparametric magnetic resonance imaging interpretation using the Prostate Imaging Reporting and Data System: a blinded comparison of radiologists. Eur Urol Focus. 2020;6:267\u201372. https:\/\/doi.org\/10.1016\/j.euf.2018.10.008.","journal-title":"Eur Urol Focus"},{"key":"1043_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00261-014-0197-7","volume":"40","author":"K Garcia-Reyes","year":"2015","unstructured":"Garcia-Reyes K, Passoni NM, Palmeri ML, Kauffman CR, Choudhury KR, Polascik TJ, et al. Detection of prostate cancer with multiparametric MRI: effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdom Imaging. 2015;40:134\u201342. https:\/\/doi.org\/10.1007\/s00261-014-0197-7.","journal-title":"Abdom Imaging"},{"key":"1043_CR22","doi-asserted-by":"publisher","first-page":"djv095","DOI":"10.1093\/jnci\/djv095","volume":"107","author":"RJ Bryant","year":"2015","unstructured":"Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. 2015;107:djv095 https:\/\/doi.org\/10.1093\/jnci\/djv095.","journal-title":"J Natl Cancer Inst"},{"key":"1043_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41391-018-0074-5","volume":"22","author":"\u00c1 Borque-Fernando","year":"2019","unstructured":"Borque-Fernando \u00c1, Rubio-Briones J, Esteban LM, Dong Y, Calatrava A, Gomez-Ferrer \u00c1, et al. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. Prostate Cancer Prostatic Dis. 2019;22:84\u201390. https:\/\/doi.org\/10.1038\/s41391-018-0074-5.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1043_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41391-024-00898-w","volume":"28","author":"HY Hougen","year":"2025","unstructured":"Hougen HY, Reis IM, Han S, Prakash NS, Thomas J, Stoyanova R, et al. Evaluating 4Kscore\u2019s role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score. Prostate Cancer Prostatic Dis. 2025;28:180\u20136. https:\/\/doi.org\/10.1038\/s41391-024-00898-w.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1043_CR25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.eururo.2016.11.017","volume":"72","author":"DW Lin","year":"2017","unstructured":"Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, et al. Evaluating the four kallikrein panel of the 4Kscore for prediction of high-grade prostate cancer in men in the Canary Prostate Active Surveillance Study. Eur Urol. 2017;72:448\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2016.11.017.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01043-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01043-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01043-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:41:43Z","timestamp":1779331303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01043-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1043"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01043-x","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SP is a consultant for OPKO Health, the provider of the 4Kscore test. All other authors (TG, ON, J.P, TF, GR, AW. JR, KZ, EC, PF, AK, BN, CR, MG, DP) declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the University of Miami Institutional Review Board (IRB) under IRB#20140785. This study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}